11th International Congress of Parkinson's Disease and Movement Disorders

 
 

11th International Congress of Parkinson's Disease and Movement Disorders

  • New and Improved UPDRS on the Way Within the next year, clinicians can expect a new and improved Unified Parkinson's Disease Rating Scale, the current gold standard and most widely used clinical assessment tool for Parkinson's disease in the world.
  • Serum BDNF May Be Useful Biomarker in Huntington's Disease A new study shows a relationship between the HD mutation and reduced levels of brain-derived neurotrophic factor in the serum of patients, suggesting it may provide a useful clinical marker in the disease.
  • Dopaminergic Agonists Linked to Compulsions in RLS Like their counterparts with Parkinson's disease, patients with restless legs syndrome taking dopaminergic agonists are at increased risk for compulsive behaviors, new research suggests.
  • Iron Deficiency in All Brain Regions Underlies RLS A new MRI study from German researchers shows a significant decrease in tissue iron content across virtually all brain regions in idiopathic RLS patients, implicating iron metabolism in the pathophysiology of this condition.
  • Device Rivals Clinicians' Assessment of Parkinson's Disease Symptoms A promising new device has been shown to objectively assess upper-extremity symptoms in Parkinson's disease patients with more than 80% accuracy, rivaling that of physician assessment with the Unified Parkinson's Disease Rating Scale.
  • Factors Associated with Hypersexuality in PD Patients Male gender, younger age at Parkinson's disease onset, comorbid major depression, and novelty seeking are associated with increased risk for pathological hypersexuality in response to treatment with dopamine agonists, a new study suggests.
  • NNIPPS: No Benefit of Riluzole on Survival in MSA and PSP Results of a randomized trial of the neuroprotectant drug riluzole in patients with so-called "Parkinson plus syndromes" of multiple system atrophy and progressive supranuclear palsy show no effect on survival vs placebo.
  • DBS Has Sustained Positive Impact on Quality of Life in Severe Dystonia New research shows pallidal deep brain stimulation in severe, medically refractory dystonia patients has a sustained effect in improving physical symptoms and consequently has a positive, sustained impact on health-related quality of life.